Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression.
COVID-19 severity
Hydroxybutyrate dehydrogenase
Mortality
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
08
2021
accepted:
06
11
2021
pubmed:
21
11
2021
medline:
26
10
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Alterations in cardiac and renal biomarkers have been reported in coronavirus disease 19 (COVID-19). We conducted a systematic review and meta-analysis to investigate serum concentrations of hydroxybutyrate dehydrogenase (HBDH), a combined marker of myocardial and renal injury, in hospitalized COVID-19 patients with different disease severity and survival status. We searched PubMed, Web of Science and Scopus, between December 2019 and April 2021, for studies reporting HBDH in COVID-19. Risk of bias was assessed using the Newcastle-Ottawa scale, publication bias was assessed with the Begg's and Egger's tests, and certainty of evidence was assessed using GRADE. In 22 studies in 15,019 COVID-19 patients, serum HBDH concentrations on admission were significantly higher in patients with high disease severity or non-survivor status when compared to patients with low severity or survivor status (standardized mean difference, SMD = 0.90, 95% CI 0.74 to 1.07, p < 0.001; moderate certainty of evidence). Extreme between-study heterogeneity was observed (I
Identifiants
pubmed: 34799779
doi: 10.1007/s10238-021-00777-x
pii: 10.1007/s10238-021-00777-x
pmc: PMC8603904
doi:
Substances chimiques
Biomarkers
0
Hydroxybutyrate Dehydrogenase
EC 1.1.1.30
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-508Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–22. https://doi.org/10.1056/NEJMra2026131 .
doi: 10.1056/NEJMra2026131
pubmed: 33264547
pmcid: 7727315
Hirawat R, Saifi MA, Godugu C. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. Life Sci. 2021;267:118923. https://doi.org/10.1016/j.lfs.2020.118923 .
doi: 10.1016/j.lfs.2020.118923
pubmed: 33358906
Thakur V, Ratho RK, Kumar P, et al. Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J Clin Med. 2021;10(3):446. https://doi.org/10.3390/jcm10030446 .
doi: 10.3390/jcm10030446
pubmed: 33498861
pmcid: 7866189
Raghavan S, Gayathri R, Kancharla S, Kolli P, Ranjitha J, Shankar V. Cardiovascular impacts on COVID-19 infected patients. Front Cardiovasc Med. 2021. https://doi.org/10.3389/fcvm.2021.670659 .
doi: 10.3389/fcvm.2021.670659
pubmed: 34179146
pmcid: 8225996
Punj S, Eng E, Shetty AA. Coronavirus disease 2019 and kidney injury. Curr Opin Nephrol Hypertens. 2021;30:444–9. https://doi.org/10.1097/MNH.0000000000000718 .
doi: 10.1097/MNH.0000000000000718
pubmed: 34027906
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811–8. https://doi.org/10.1001/jamacardio.2020.1017 .
doi: 10.1001/jamacardio.2020.1017
pubmed: 32219356
Ng JH, Hirsch JS, Hazzan A, et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis. 2021;77(204–15): e1. https://doi.org/10.1053/j.ajkd.2020.09.002 .
doi: 10.1053/j.ajkd.2020.09.002
Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells. 2020. https://doi.org/10.3390/cells9112508 .
doi: 10.3390/cells9112508
pubmed: 33228225
pmcid: 7699571
Centurion OA, Scavenius KE, Garcia LB, Torales JM, Mino LM. Potential mechanisms of cardiac injury and common pathways of inflammation in patients with COVID-19. Crit Pathw Cardiol. 2021;20:44–52. https://doi.org/10.1097/HPC.0000000000000227 .
doi: 10.1097/HPC.0000000000000227
pubmed: 32467423
Ahmadian E, HosseiniyanKhatibi SM, RaziSoofiyani S, et al. Covid-19 and kidney injury: pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31:e2176. https://doi.org/10.1002/rmv.2176 .
doi: 10.1002/rmv.2176
pubmed: 33022818
Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46–64. https://doi.org/10.1038/s41581-020-00357-4 .
doi: 10.1038/s41581-020-00357-4
pubmed: 33077917
Yang J, Liao X, Yin W, et al. Elevated cardiac biomarkers may be effective prognostic predictors for patients with COVID-19: a multicenter, observational study. Am J Emerg Med. 2021;39:34–41. https://doi.org/10.1016/j.ajem.2020.10.013 .
doi: 10.1016/j.ajem.2020.10.013
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. China JAMA Cardiol. 2020;5:802–10. https://doi.org/10.1001/jamacardio.2020.0950 .
doi: 10.1001/jamacardio.2020.0950
pubmed: 32211816
Mangoni AA, Erre GL. Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages. Ther Adv Drug Saf. 2021;12:2042098621998876. https://doi.org/10.1177/2042098621998876 .
doi: 10.1177/2042098621998876
pubmed: 33796258
pmcid: 7968020
van der Laarse A, Davids HA, Hollaar L, van der Valk EJ, Witteveen SA, Hermens WT. Recognition and quantification of myocardial injury by means of plasma enzyme and isoenzyme activities after cardiac surgery. Br Heart J. 1979;41:660–7. https://doi.org/10.1136/hrt.41.6.660 .
doi: 10.1136/hrt.41.6.660
pubmed: 313803
pmcid: 482088
de Zwaan C, Willems GM, Vermeer F, et al. Enzyme tests in the evaluation of thrombolysis in acute myocardial infarction. Br Heart J. 1988;59:175–83. https://doi.org/10.1136/hrt.59.2.175 .
doi: 10.1136/hrt.59.2.175
pubmed: 3342158
pmcid: 1276981
Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J. 2006;152:1161–7. https://doi.org/10.1016/j.ahj.2006.07.016 .
doi: 10.1016/j.ahj.2006.07.016
pubmed: 17161070
Dissmann R, Linderer T, Schroder R. Estimation of enzymatic infarct size: direct comparison of the marker enzymes creatine kinase and alpha-hydroxybutyrate dehydrogenase. Am Heart J. 1998;135:1–9. https://doi.org/10.1016/s0002-8703(98)70335-7 .
doi: 10.1016/s0002-8703(98)70335-7
pubmed: 9453514
Kemp M, Donovan J, Higham H, Hooper J. Biochemical markers of myocardial injury. Br J Anaesth. 2004;93:63–73. https://doi.org/10.1093/bja/aeh148 .
doi: 10.1093/bja/aeh148
pubmed: 15096441
Apostolov I, Minkov N, Koycheva M, et al. Acute changes of serum markers for tissue damage after ESWL of kidney stones. Int Urol Nephrol. 1991;23:215–20. https://doi.org/10.1007/BF02550414 .
doi: 10.1007/BF02550414
pubmed: 1889966
van der Veen FH, Visser R, Willems GM, Kop-Klaassen B, Hermens WT. Myocardial enzyme depletion in infarcted human hearts: infarct size and equivalent tissue mass. Cardiovasc Res. 1988;22:611–9. https://doi.org/10.1093/cvr/22.9.611 .
doi: 10.1093/cvr/22.9.611
pubmed: 3242832
Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. StatPearls. (2021) Treasure Island (FL).
Zinellu A, Mangoni AA. Serum prealbumin concentrations, COVID-19 severity, and mortality: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:638529. https://doi.org/10.3389/fmed.2021.638529 .
doi: 10.3389/fmed.2021.638529
Zinellu A, Paliogiannis P, Carru C, Mangoni AA. Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis. Int J Infect Dis. 2021;105:668–74. https://doi.org/10.1016/j.ijid.2021.03.025 .
doi: 10.1016/j.ijid.2021.03.025
pubmed: 33737133
pmcid: 7959678
Wells GA, Shea B, O’Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses The Ottawa Hospital Research Institute 2013 [cited 2020 20/11/2020]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ, USA: Erlbaum; 1988.
Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3 Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–16. https://doi.org/10.1016/j.jclinepi.2010.07.015 .
doi: 10.1016/j.jclinepi.2010.07.015
pubmed: 21208779
Hultcrantz M, Rind D, Akl EA, et al. The GRADE working group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4–13. https://doi.org/10.1016/j.jclinepi.2017.05.006 .
doi: 10.1016/j.jclinepi.2017.05.006
pubmed: 28529184
pmcid: 6542664
Zhang Y, Coello PA, Guyatt GH, et al. GRADE guidelines: 20 Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93. https://doi.org/10.1016/j.jclinepi.2018.05.011 .
doi: 10.1016/j.jclinepi.2018.05.011
pubmed: 29800687
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135 .
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41. https://doi.org/10.1186/1471-2288-11-41 .
doi: 10.1186/1471-2288-11-41
pubmed: 21473747
pmcid: 3102034
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. https://doi.org/10.1002/sim.1186 .
doi: 10.1002/sim.1186
pubmed: 12111919
Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technical Bulletin. 1999;47:15–7.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
doi: 10.2307/2533446
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046–55. https://doi.org/10.1016/s0895-4356(01)00377-8 .
doi: 10.1016/s0895-4356(01)00377-8
pubmed: 11576817
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. https://doi.org/10.1111/j.0006-341x.2000.00455.x .
doi: 10.1111/j.0006-341x.2000.00455.x
pubmed: 10877304
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71 .
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Ali A, Noman M, Guo Y, et al. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Sci Rep. 2021;11:5975. https://doi.org/10.1038/s41598-021-85426-9 .
doi: 10.1038/s41598-021-85426-9
pubmed: 33727641
pmcid: 7971049
Bai Y, Wang E, Zhao S, et al. Implications of laboratory tests in disease grading and death risk stratification of COVID-19: a retrospective study in Wuhan. China Front Med (Lausanne). 2021;8: 629296. https://doi.org/10.3389/fmed.2021.629296 .
doi: 10.3389/fmed.2021.629296
Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clin Microbiol Infect. 2020;26:1242–7. https://doi.org/10.1016/j.cmi.2020.05.041 .
doi: 10.1016/j.cmi.2020.05.041
pubmed: 32526275
pmcid: 7280135
Cheng JP, Liu WX, Chen SY, et al. Abnormal myocardial enzymes are important indicators of poor prognosis in COVID-19 patients. Futur Virol. 2021;16:265–76. https://doi.org/10.2217/fvl-2020-0304 .
doi: 10.2217/fvl-2020-0304
Dong X, Sun L, Li Y. Prognostic value of lactate dehydrogenase for in-hospital mortality in severe and critically ill patients with COVID-19. Int J Med Sci. 2020;17:2225–31. https://doi.org/10.7150/ijms.47604 .
doi: 10.7150/ijms.47604
pubmed: 32922185
pmcid: 7484664
Dong Y, Zhou H, Li M, et al. A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection. Transbound Emerg Dis. 2020;67:2823–9. https://doi.org/10.1111/tbed.13651 .
doi: 10.1111/tbed.13651
pubmed: 32469137
pmcid: 7283685
Guo J, Zhou B, Zhu M, et al. CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study. Epidemiol Infect. 2020;148: e241. https://doi.org/10.1017/S0950268820002368 .
doi: 10.1017/S0950268820002368
pubmed: 32998791
Huang J, Zhu L, Bai X, et al. Multidimensional analysis of risk factors for the severity and mortality of patients with COVID-19 and diabetes. Infect Dis Ther. 2020;9:981–1002. https://doi.org/10.1007/s40121-020-00359-6 .
doi: 10.1007/s40121-020-00359-6
pubmed: 33113119
pmcid: 7591692
Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148: e139. https://doi.org/10.1017/S0950268820001557 .
doi: 10.1017/S0950268820001557
pubmed: 32641174
Li P, Wu W, Zhang T, et al. Implications of cardiac markers in risk-stratification and management for COVID-19 patients. Crit Care. 2021;25:158. https://doi.org/10.1186/s13054-021-03555-z .
doi: 10.1186/s13054-021-03555-z
pubmed: 33902676
pmcid: 8074282
Liu W, Liu Y, Xu Z, et al. Clinical characteristics and predictors of the duration of SARS-CoV-2 viral shedding in 140 healthcare workers. J Intern Med. 2020;288:725–36. https://doi.org/10.1111/joim.13160 .
doi: 10.1111/joim.13160
pubmed: 32959400
pmcid: 7537050
Ma X, Wang H, Huang J, et al. A nomogramic model based on clinical and laboratory parameters at admission for predicting the survival of COVID-19 patients. BMC Infect Dis. 2020;20:899. https://doi.org/10.1186/s12879-020-05614-2 .
doi: 10.1186/s12879-020-05614-2
pubmed: 33256643
pmcid: 7702207
Qin S, Li W, Shi X, et al. 3044 Cases reveal important prognosis signatures of COVID-19 patients. Comput Struct Biotechnol J. 2021;19:1163–75. https://doi.org/10.1016/j.csbj.2021.01.042 .
doi: 10.1016/j.csbj.2021.01.042
pubmed: 33584997
pmcid: 7870437
Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: a multicentre retrospective study. Epidemiol Infect. 2020;148: e238. https://doi.org/10.1017/S0950268820002332 .
doi: 10.1017/S0950268820002332
pubmed: 32993821
Song CY, Xu J, He JQ, Lu YQ. Immune dysfunction following COVID-19, especially in severe patients. Sci Rep. 2020;10:15838. https://doi.org/10.1038/s41598-020-72718-9 .
doi: 10.1038/s41598-020-72718-9
pubmed: 32985562
pmcid: 7522270
Wang J, Guo S, Zhang Y, et al. Clinical features and risk factors for severe inpatients with COVID-19: a retrospective study in China. PLoS ONE. 2020;15: e0244125. https://doi.org/10.1371/journal.pone.0244125 .
doi: 10.1371/journal.pone.0244125
pubmed: 33332437
pmcid: 7745975
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan. China JAMA Intern Med. 2020;180:934–43. https://doi.org/10.1001/jamainternmed.2020.0994 .
doi: 10.1001/jamainternmed.2020.0994
pubmed: 32167524
Xiao J, Li X, Xie Y, et al. Maximum chest CT score is associated with progression to severe illness in patients with COVID-19: a retrospective study from Wuhan. China BMC Infect Dis. 2020;20:953. https://doi.org/10.1186/s12879-020-05683-3 .
doi: 10.1186/s12879-020-05683-3
pubmed: 33308183
Xie J, Shi D, Bao M, et al. A predictive nomogram for predicting improved clinical outcome probability in patients with COVID-19 in Zhejiang Province. China Engineering (Beijing). 2020. https://doi.org/10.1016/j.eng.2020.05.014 .
doi: 10.1016/j.eng.2020.05.014
pubmed: 33449771
pmcid: 7746569
Yan X, Li F, Wang X, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. J Med Virol. 2020;92:2573–81. https://doi.org/10.1002/jmv.26061 .
doi: 10.1002/jmv.26061
pubmed: 32458459
pmcid: 7283791
Yu Y, Zhu C, Yang L, et al. Identification of risk factors for mortality associated with COVID-19. PeerJ. 2020;8: e9885. https://doi.org/10.7717/peerj.9885 .
doi: 10.7717/peerj.9885
pubmed: 32953279
pmcid: 7473053
Zheng X, Chen J, Deng L, et al. Risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. J Med Virol. 2021;93:952–9. https://doi.org/10.1002/jmv.26367 .
doi: 10.1002/jmv.26367
pubmed: 32725915
Anttinen H, Jarvensivu PM, Savolainen ER. Serum galactosylhydroxylysyl glucosyltransferase in acute myocardial infarction and during subsequent collagen scar formation. Eur J Clin Invest. 1981;11:375–3. https://doi.org/10.1111/j.1365-2362.1981.tb01999.x .
doi: 10.1111/j.1365-2362.1981.tb01999.x
pubmed: 6460637
Huang ZQ, Shi GG, Zheng JH, Liu B. Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium current. Acta Pharmacol Sin. 2003;24:757–7.
pubmed: 12904274
Li AL, Gao LX. Protection of branched-chain amino acids against ischemic myocardial injury in rats. Biomed Environ Sci. 1999;12:62–6.
pubmed: 10442223
Slezak J, Tribulova N, Ravingerova T, Singal PK. Myocardial heterogeneity and regional variations in response to injury. Lab Invest. 1992;67:322–3.
pubmed: 1405491
Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736–17. https://doi.org/10.1183/09031936.96.09081736 .
doi: 10.1183/09031936.96.09081736
pubmed: 8866602
Siriwardane D, Woodman R, Hakendorf P, et al. Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service. Clin Med (Lond). 2010;10:540–5. https://doi.org/10.7861/clinmedicine.10-6-540 .
doi: 10.7861/clinmedicine.10-6-540